ERLOTINIB IN METASTATIC, EGFR WILD-TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS SECOND OR FURTHER LINE OF THERAPY

被引：0
|
作者：
Hernandez, Alba [1 ]
Calera, Lourdes [1 ]
Alvarez, Maria [1 ]
Hernando, Jorge [1 ]
Torres, Irene [1 ]
Pajares, Isabel [1 ]
Madani, Julia [1 ]
Cebollero, Ana [1 ]
Anton-Torres, Antonio [1 ]
Artal, Angel [1 ]
机构：
[1] Hosp Univ Miguel Servet, Zaragoza, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
erlotinib; second line; wild-type EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.24-036
引用
收藏
页码：S1017 / S1017
页数：1
相关论文
共 50 条
  • [1] Clinical and biological significance of erlotinib therapy after pemetrexed in non-small cell lung cancer with wild-type EGFR
    Koyama, N.
    Suzuki, M.
    NEOPLASMA, 2015, 62 (06) : 996 - 1004
  • [2] A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
    Wang, Duo
    Zhou, Jun
    Fang, Weimin
    Huang, Cuiqing
    Chen, Zerong
    Fan, Meng
    Zhang, Ming-Rong
    Xiao, Zeyu
    Hu, Kuan
    Luo, Liangping
    BIOACTIVE MATERIALS, 2022, 13 : 312 - 323
  • [3] Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data
    Debieuvre, D.
    Moreau, L.
    Coudert, M.
    Locher, C.
    Asselaine, B.
    Coetmeur, D.
    Dayen, C.
    Goupil, F.
    Martin, F.
    Brun, P.
    De Faverges, G.
    Hauss, P-A
    Gally, S.
    Yahia, B. Ben Hadj
    Grivauxd, M.
    REVUE DES MALADIES RESPIRATOIRES, 2019, 36 (06) : 649 - 663
  • [4] Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
    Raimbourg, Judith
    Joalland, Marie-Pierre
    Cabart, Mathilde
    de Plater, Ludmilla
    Bouquet, Fanny
    Savina, Ariel
    Decaudin, Didier
    Bennouna, Jaafar
    Vallette, Francois M.
    Lalier, Lisenn
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (08) : 1634 - 1644
  • [5] Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report
    Polychronidou, Genovefa
    Papakotoulas, Pavlos
    CASE REPORTS IN ONCOLOGY, 2013, 6 (01): : 189 - 196
  • [6] Combining forces: Synergy of erlotinib and crizotinib in a wild-type squamous non-small cell lung cancer cell line
    Van der Steen, Nele
    Rolfo, Christian
    Pauwels, Patrick
    Peters, Godefridus J.
    Giovannetti, Elisa
    CANCER RESEARCH, 2017, 77
  • [7] The efficacy of erlotinib for patients with non-small cell lung cancer with wild type of EGFR mutations
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Tanabe, Tsuyoshi
    Tsushima, Kenji
    Urushihata, Kazuhisa
    Yamamoto, Hiroshi
    Hanaoka, Masayuki
    Kubo, Keishi
    Koyama, Shigeru
    Ooura, Nariaki
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S690 - S690
  • [8] Efficacy and safety of anlotinib monotherapy or combination therapy as second-line therapy in EGFR-wild-type non-small cell lung cancer (NSCLC) patients
    Guo, J.
    Wang, X.
    Zheng, F.
    Zhao, G.
    Wang, Y.
    Hu, Y.
    Liu, P.
    Ma, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1012 - S1012
  • [9] Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Sequist, Lecia, V
    Gray, Jhanelle Elaine
    Harb, Wael A.
    Lopez-Chavez, Ariel
    Doebele, Robert C.
    Modiano, Manuel R.
    Jackman, David Michael
    Baggstrom, Maria Quintos
    Atmaca, Akin
    Felip, Enriqueta
    Provencio, Mariano
    Cobo, Manuel
    Adiwijaya, Bambang
    Kuesters, Geoffrey
    Kamoun, Walid S.
    Andreas, Karen
    Pipas, J. Marc
    Santillana, Sergio
    Cho, Byoung Chul
    Park, Keunchil
    Shepherd, Frances A.
    ONCOLOGIST, 2019, 24 (08): : 1095 - 1102
  • [10] Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Sequist, L.
    Gray, J.
    Harb, W.
    Doebele, R.
    Modiano, M.
    Jackman, D.
    Baggstrom, M.
    Atmaca, A.
    Felip, E.
    Provencio, M.
    Cobo Dols, M.
    Adiwijaya, B.
    Kuesters, G.
    Kamoun, W.
    Andreas, K.
    Pipas, J.
    Santillana, S.
    Cho, B. C.
    Park, K.
    Shepherd, F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S596 - S596
12345